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Abstract
Background: Pravastatin, a known inducer of endothelial nitric-oxide synthase (eNOS) was demonstrated in human
placenta, however the exact mechanism of it’s action is not fully understood. Since placental NO (nitric oxide)
synthesis is of primary importance in the regulation of placental blood flow, we aimed to clarify the effects of
pravastatin on healthy (n = 6) and preeclamptic (n = 6) placentas (Caucasian participants).
Methods: The eNOS activity of human placental microsomes was determined by the conversion rate of C14 L-arginine
into C14 L-citrulline with or without pravastatin and Geldanamycin. Phosphorylation of eNOS (Ser1177) was
investigated by Western blot. Microsomal arginine uptake was measured by a rapid filtration method.
Results: Pravastatin significantly increased total eNOS activity in healthy (28%, p<0.05) and preeclamptic placentas
(32%, p<0.05) using 1mM Ca2+ promoting the dissociation of a eNOS from it’s inhibitor caveolin. Pravastatin and
Geldanamycin (Hsp90 inhibitor) cotreatment increased microsomal eNOS activity. Pravastatin treatment had no
significant effects on Ser1177 phosphorylation of eNOS in either healthy or preeclamptic placentas. Pravastatin induced
arginine uptake of placental microsomes in both healthy (38%, p < 0.05) and preeclamptic pregnancies (34%, p < 0.05).
Conclusions: This study provides a novel mechanism of pravastatin action on placental NO metabolism. Pravastatin
induces the placental microsomal arginine uptake leading to the rapid activation of eNOS independently of Ser1177
phosphorylation. These new findings may contribute to better understanding of preeclampsia and may also have a
clinical relevance.
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Background
Preeclamsia is a gestational disorder characterized by
hypertension and proteinuria, and is one of the lead-
ing cause of maternal and fetal mortality affecting 2–
8% of all pregnancies [1, 2]. Since there have been no
effective methods for its prevention and treatment,
there is an urgent need to better understanding of
the underlying mechanisms [3].
Preeclampsia is associated with widespread endothelial
damage and decreased NO (nitric oxide) bioavailability. NO
is produced by NO synthase from L-arginine, O2 and
NADPH. Principally endothelial NO synthase (eNOS) iso-
enzyme is expressed by the human placenta [3], thus pla-
centa has a crucial role in the development of preeclampsia.
The enzyme activity of eNOS is tightly regulated by sev-
eral factors. eNOS activity is increased by elevated Ca2+ and
tetrahydrobiopterin (BH4) levels, through its phosphoryl-
ation on Ser1177 by numerous kinases and dephosphoryla-
tion on Thr495 by phosphatases [3], and also by binding to
the chaperone Hsp90. eNOS is activated by the bond of
Hsp90. The Hsp90 inhibitors such as geldanamycin inter-
act with the ATP binding site of Hsp90. Geldanamycin-
bound Hsp90 resembles the ADP-binding conformation
of the chaperone, and the replacement of ADP by ATP is
not possible [4]. On the other hand, eNOS activity is
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decreased by the endogenous competitive inhibitor asym-
metric dimethylarginine, through its dephosphorylation
on Ser1177 and phosphorylation on Thr495 or by binding
to caveolin-1, the scaffolding protein of caveolae [5, 6].
The activity of eNOS has been demonstrated to be also
affected by pharmacological activators, statins. Statins are
the known inhibitors of the rate-limiting enzyme of chol-
esterol biosynthesis, 3-hydroxy-3-methyl-3-glutaryl-Coen-
zyme A reductase [7]. Most recent statin therapies are
based on their cholesterol lowering effects. They also have
anti-diabetic, anti-inflammatory, antioxidant, neuroprotec-
tive, proangiogenic and anti-thrombotic properties, thus
contributing to the endothelial protection. Moreover, sta-
tins were shown to decrease systolic and diastolic blood
pressure in healthy and hypertonic participants [8, 9].
These protective effects of statins suggest that they have
the therapeutic potential to treat preeclampsia.
Studies have shown that pravastatin can lower blood
pressure and improve proteinuria in some preeclampsia-
like rodent models (Nω-nitro-L-arginine methyl ester, in-
hibitor of eNOS and soluble vascular endothelial growth
factor 1 receptor (sVEGFR-1)-induced mouse model) [10].
Statins affect eNOS activity in distinct ways, increasing
eNOS expression by prolonging eNOS mRNA half-life.
Simvastatin and lovastatin increase eNOS expression in
human saphenous vein endothelial cell culture [11]. Sta-
tins modify the activity of eNOS by its phosphorylation
on Ser615, Ser633 and Ser1177. Statins can activate the
phosphatidylinositol 3-kinase (PI3K)/Akt pathway [12]
and activate eNOS through the phosphorylation of
Ser1177 and dephosphorylation on Thr495. Microsomes
(subcellular fractions including endoplasmatic reticulum
and cell membrane) have the highest activity of eNOS
between placental subcellular fractions [13].
Figure 1 includes potential effect sites of pravastatin
on rapid eNOS activity.
Recently, the first randomized pilot clinical study in
humans has been published. In this study 20 high-risk
patients (with a history of severe preeclampsia in a prior
pregnancy) were treated with pravastatin versus placebo
during pregnancy. While 40% of the placebo treated pa-
tients developed preeclampsia, patients that received
pravastatin have not developed preeclampsia [14].
The teratogen effect of statin treatment under pregnancy
is controversial. The risk of teratogenicity of statins appears
to be relatively low according to a human study including
women with hypercholesterolaemia (n = 64). Infants in the
statin treated group had lower birth weight and shorter ges-
tation period [15]. In a recent pilot clinical study, 40mg
pravastatin resolved the symptoms of preeclampsia of the
patients. Blood pressure and urine protein/creatinine ratio
of many participants had stabilized. Pravastatin was well
tolerated, and there were no fetal or neonatal abnormalities
at birth. Pravastatin reduced sVEGFR secretion from pre-
eclamptic placenta in vitro [16].
Methods
Patients and human samples
Clinical data of the participants (control and preeclamptic
pregnant patients) are shown as mean ± SD in Table 1
Fig. 1 Potential effect sites of pravastatin on rapid eNOS activity
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collected from medical records. Eligible preeclamptic cau-
casian race pregnant women have been diagnosed with
preeclampsia according to the following criteria: presence
of pregnancy-induced hypertension (systolic ≥140mmHg,
diastolic ≥90mmHg) and proteinuria (≥300mg/24 h or at
least 2+) after the 20th week of gestation. Healthy cauca-
sian race women with normal pregnancy were selected as
controls, showing no signs of preeclampsia or other pla-
cental diseases. Participants were not treated with prava-
statin during pregnancy. Written informed consent was
signed by all participants to confirm their agreement to
participate at the study. Human placentae were obtained
randomly from 6 normal and 6 preeclamptic pregnancies
at the 2nd Department of Obstetrics and Gynecology,
Semmelweis University, Budapest, Hungary. All of our ex-
periments were permitted by the Ethics Committee of the
Medical Section of The Hungarian Academy of Sciences
(Permisson No. 48995–2016/EKU). Placental tissue was
immediately put into ice-cold transfer solution containing
0.9% NaCl, 40mM HEPES/Na (pH = 7.4) and l mg/ml glu-
cose and was transported immediately to the biochemical
laboratory where the experiment was started without delay.
Preparation of placental microsomes
The preparation of placental microsomes (MS) was carried
out as previously reported [13]. Macroscopically isolated
placental tissue mince was homogenized in 2 volume of
ice-cold homogenizing solution containing 0.3M sucrose,
40mM HEPES/Na, pH = 7.4, 0.1mM EDTA, 1mM dithio-
threitol, 1mM phenylmethanesulfonyl fluoride, 10 μg/ml
leupeptin, 10 μg/ml soybean trypsin inhibitor and 0.2 μg/ml
aprotinin, using an UltraTurrax apparatus (IKA Werk,
Staufen, Germany) at the three-quarter setting for 60 s. The
homogenate produced by the UltraTurrax apparatus was
filtered through a nylon mesh and cell debris and tissue
fragments were removed by 2min centrifugation at 600 g
using a Janetzky K-24 refrigerated centrifuge. In order to
separate cytosol and microsomal fractions, heavy particulate
material and mitochondria were sedimented first at 15000 g
for 30min in a Beckman J2-HS centrifuge. The supernatant
was then centrifuged at 100000 g for 60min in a Beckman
OptimaTM LE-80 K ultracentrifuge to obtain the micro-
somal pellet and the cytosol fraction. The pellet (MS frac-
tion) was suspended in homogenizing solution. MS fraction
was used immediatly to measure eNOS activity or refriger-
ated for further analysis at − 80 °C for western blot, or in li-
quid nitroge+ n for arginine uptake measurements.
Measurement of eNOS activity
Determination of NOS activity was performed by measur-
ing the rate of conversion of radiolabelled L-arginine into
radiolabelled L-citrulline as previously described [17, 18].
Control eNOS activities were determined without prava-
statin. The eNOS activities were measured at 1mM CaCl2,
and 50 μM BH4 added in all experiments. In a typical
experiment 3.5–5.5mg MS protein was incubated.
Western blot analysis of eNOS phosphorylation
MS fraction was solved in sample buffer (2% sodium-
dodecyl sulfat (SDS), 10mM dithiothreitol), boiled for 5
min, and 50 μg protein was electrophoresed on 7.5% SDS–
polyacrylamide gels. Electrophoresis was performed at 29
mA for 2 h using the Miniprotean II setup placed in ice-
bath. Proteins were transferred to polyvinylidene difluoride
(PVDF) membranes for 3 h at 290mA, membranes were
blocked overnight at 4 °C with TBST solution (20mM Tris/
HCl, pH 7.5, 100mM NaCl, 0.1% Tween 20) containing 5%
bovine serum albumine. Anti-eNOS was used a dilution of
1:1000 at room temperature for 2 h. Peroxidase-conjugated
secondary antibody was used at 1:5000 dilution for 1 h at
room temperature. Signals were developed by 1min incuba-
tion with West-One chemiluminescent substrate and ex-
posed to X-ray films for 0.5–5min. Developed films were
scanned using an Ultrascan XL Laser Densitometer.
Measurement of microsomal arginine uptake by rapid
filtration method
Arginine uptake of placental MS were determinated by
rapid filtration experiments. These determinations were
essentially performed as described by Bánhegyi et al.
[19] adapted to arginine uptake. MS (1 mg protein/ml)
were incubated at 25 °C in microsomal homogenisating
buffer (0.3M sucrose, 40mM HEPES/Na (pH= 7.4), 1mM
EDTA, 1mM dithiotreitol, 1mM PMSF, 10 μg/ml aproti-
nin, 10 μg/ml soytrypsin inhibitor, 5 μg/ml leupeptin) with
or without 10 μM pravastatin for 10min. This time
0.5 μCi C14 arginine has been added to the sample. At the
indicated times 100 μl aliquots were withdrawn, filtered
through cellulose acetate/nitrate filter membranes (pore
size 0.22 μm), and quickly washed twice through the
filter with 3 ml ice-cold homogenisating buffer con-
taining 10 mM ornithine. The radioactivity retained
on the filter was measured after the dissolvance of
the filter by liquid scintillation. Alamethicin (50 μg/
Table 1 Clinical data of participants
Control
pregnancies
Preeclamptic
pregnancies
Maternal age (years) 29.0 ± 3.3 31.2 ± 2.3 n.s.
Delivery (weeks) 39.8 ± 0.4 33.5 ± 3.0***
Systolic blood pressure
(Hgmm)
109.2 ± 8.6 163.3 ± 19.7***
Diastolic blood pressure
(Hgmm)
74.0 ± 7.9 103.3 ± 8.2***
Proteinuria 0 ++
Weight of fetus (g) 3435 ± 149 1993 ± 784***
n.s.not significant
***= p<0.001
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mg protein) has been included in parallel samples to
distinguish the intravesicular radioactivities from the
bound radioactivities. The alamethicin-releasable por-
tion of radioactivity (assumed as intravesicular) was
calculated by subtraction.
Protein determinations
Protein was measured by the method of Lowry et al. [20]
using bovine serum albumin as standard.
Statistical analysis
Results were statistically evaluated by using Excel Data
analysis softwares. The difference was accepted
significant if p < 0.05. Test for statistically significant dif-
ferences (p < 0.05) was performed by analysis of t-test.
Data are given as mean ± SD for 3–6 separate
experiments.
Materials
L-[U-14C] arginine (348 mCi/mmol; 12.9 GBq/mmol)
were purchased from ICN (Costa Mesa, CA, USA). (6R)-
5,6,7,8-tetrahydro-L-biopterin (BH4) was obtained from
Research Biochemicals International (Natick, MA, USA).
L-NG-nitroarginine methylester, NADPH, Dowex 50X8–
400, dithiothreitol, L-citrulline, L-arginine, L-ornithine,
calmodulin, leupeptin, alamethicin were from Sigma-
Fig. 2 ,,A'' Microsomal eNOS activity. ,,B'' Effect of pravastatin on relative microsomal eNOS activity. These activities are the control data (100 %)
of Figure 2. b. Activities are eNOS activity without pravastatin. Ca= 1 mM Ca2+; Ca, BH4= 1 mM Ca2+, 50 μM BH4. **= p<0.01, ***= p<0.001. Error
bars show SD values (n=6). 100 % activities are eNOS activity without pravastatin. Ca, Pra= 1 mM Ca2+, 10 μM Pra; Ca, BH4, Pra= 1 mM Ca2+, 50
μM BH4, 10 μM pravastatin. *= p<0.05. Error bars show SD values (n=6)
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Aldrich Kft. (Budapest, Hungary). Pravastatin, phenyl-
methylsulphonylfluoride and HEPES were from Calbio-
chem (La Jolla, CA, USA), and aprotinin from Bayer
Co. (Leverkusen, Germany). Anti-eNOS, Anti-phospho-
eNOS/NOS III (Ser1177) and donkey anti-rabbit IgG,
peroxidase conjugated were obtained from Millipore
(Boston, MA, USA). Other chemicals were from Reanal
(Budapest, Hungary).
Results
Effect of pravastatin on eNOS activity
Clinical data are summarized in Table 1. Consistent with
our previous findings, we found that 50 μM BH4 en-
hanced eNOS activity approximately 2.0–2.5-fold in both
groups (Fig. 2a). Figure 2b shows that 10 μM pravastatin
treatment increased the maximal activity of eNOS (1mM
Ca2+, 50 μM BH4) in human placental MS both in healthy
(28 ± 12%) and preeclamptic pregnancies (32 ± 10%). The
difference was not significant (p = n.s.) between control and
preeclamptic samples. The effect of pravastatin on eNOS
activity proved to be dose dependent. The eNOS activities
were increased appr. 30% by 10 μM pravastatin in 1mM
Ca2+, 50 μM BH4 (maximal activity). The activity of eNOS
is decreased by 100 and 500 μM pravastatin in similar envi-
ronments (data not shown). Caveolin inhibits eNOS in ca-
veolae, but if Ca2+ levels are increased, caveolin dissociates
from eNOS, and the enzyme is activated by 1mM Ca2+.
Pravastatin acts not only via phosphorylation of eNOS
Ser1177
Pravastatin has pleiotropic effects, including phosphoryl-
ation of eNOS Ser1177. Samples were incubated under
the same experimental condition (40 mM HEPES/Cl,
pH = 7.4; 1 mM Mg2+; 1 mM NADPH; 1 mM dithiothrei-
tol; 12 kU/L calmodulin; t = 10min; T = 37 °C; EGTA,
Ca2+, BH4 added as indicated) as used in measuring
eNOS activity without radiolabeled L-arginine and inves-
tigating the phosphorylation of eNOS Ser1177 by west-
ern blot. We found that the phosphorylation status of
microsomal eNOS Ser1177 did not change by 10 μM
pravastatin (Fig. 3).
Pravastatin action and Hsp90
ENOS is activated by the bond of Hsp90. The Hsp90
inhibitors such as geldanamycin interact with the ATP
binding site of Hsp90. Geldanamycin-bound Hsp90 re-
sembles the ADP-binding conformation of the chaperone,
and the replacement of ADP by ATP is not possible [4].
The activity of eNOS is inhibited by 100 nM geldanamycin
in both control and preeclamptic samples (Fig. 4a). Prava-
statin (10 μM) moderately increases activity of eNOS
(Fig. 4b). Geldanamycin (50 μM) attenuates NO produc-
tion by eNOS in placental MS, while added pravastatin
has no effect on eNOS activity.
Effect of pravastatin on microsomal arginine uptake
The microsomal arginine uptake was time-dependent until
the first minute. The arginine uptake was increased by
10 μM pravastatin in human placental MS both in healthy
(38 ± 9%, p < 0.05) and preeclamptic pregnancies (34 ± 1%,
p < 0.05). The difference was not significant (p > 0.05) be-
tween control and preeclamptic samples (Fig. 5).
Discussion
Our recent experiments indicate that pravastatin can
also increase eNOS activity rapidly. This effect is
Fig. 3 Effect of pravastatin on eNOS Ser1177. „A” is a typical result of western blot with anti eNOS antibody „B” is a typical result of western blot
with anti eNOS phosphorylated on Ser1177 cont t= 0 min incubation, EGTA= 1 mM EGTA, 10 min incubation; Ca= 1 mM Ca2+, 10 min
incubation and BH4=1mM Ca2+, 50 mM BH4, 10 min incubation
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independent from the phosphorylation of eNOS
Ser1177, caveolin, and Hsp90. According to our observa-
tions, activity of eNOS is increased by the rise of the en-
zyme’s substrate supply. Our findings suggest that
pravastatin may improve arginine uptake of the placenta
along with arginine substitution by insufficient arginine
levels, thus decreasing the symptoms of preeclampsia.
Our results of arginine uptake account for previous ob-
servations on the effect of statins.
Limitations of our study were: in vitro works, there are
no preeclampsia samples grouped by severity (relatively
small sample number), not classification of unknown
arginine levels in caveola (localization site of arginine
transporter and eNOS) of preeclamptic placentas. The
average plasma L-arginine levels of patients with pre-
eclampsia were significantly lower (54.2 μM) compared to
healthy controls (85.4 μM) [21]. Homogenized primordal
human placenta has 542 ± 142 μmol/kg wet tissue arginine
concentration [22]. Arginine levels in preeclamptic villi
were lower than arginine levels in homogenized villi from
control, whereas arginine levels in the decidua were com-
parable in the two groups [23]. The difference between
healthy and preeclamptic arginine concentrations may re-
sult in different eNOS activities and arginine transport.
Fig. 4 „A” Effect of 100 nM geldanamycin on eNOS relative activity of microsomes „B” The effect of pravastatin on relative eNOS activity of
geldanamycin treatment microsomes. 100 % activities are eNOS activity without pravastatin and geldanamycin. cont= 1 mM Ca2+ or 1 mM Ca2+,
50 μM BH4; Ca, Gel= 1 mM Ca2+, 100 μM Geldanamycin; Ca, BH4, Gel= 1 mM Ca2+, 50 μM BH4, 100 μM Geldanamycin. *= p<0.05. Error bars
show SD values (n=4)
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The next step is to identify the arginine transporter
that pravastatin affects.
Pravastatin stimulates human placental eNOS. Data
suggests that pravastatin has both slow and rapid effects
on eNOS activity [24–26]. Treatment of 100 nM prava-
statin results in elevated expression levels of eNOS in
human umbilical vein endothelial cell culture [27] and
200 nM pravastatin in cultures of placental explants [28].
The pravastatin induces PPARγ [29, 30] which results in
decreased FFA levels, thus the inhibition effects of FFA
on eNOS activity are reduced by pravastatin. FFA
(arachidonic acid, palmitic acid, myristic acid and
linolenic acid) decrease maximal eNOS activity in hu-
man placental MS during a short time (10 min.) incu-
bation period (Z. Kukor’s and R. Czizel’s unpublished
observations). According to data, reduced FFA levels
may increase the activity of eNOS by distinct man-
ners. Pravastatin has a short time effect on eNOS ac-
tivity as well. Pravastatin can cause elevated NO
production and vasorelaxation by phosphorylation on
eNOS Ser1177 [31]. The stimulation of eNOS might
be independent from the phosphorylation of eNOS
Ser1177.We did not add exogeneous ATP (kinase
subtrate) in our experiments. We found in our previ-
ous work that small molecules (arginine) were re-
moved from MS by ultracentrifugation [22]. We
suppose that MS still contains a small amount of its
original ATP content, but 10 μM pravastatin does not
cause phophorylation of eNOS Ser1177.
The presented results of arginine uptake may explain
previous observations regarding to the effect of statins.
Böger et al. investigated the effect of simvastatin on
healthy volunteers’ endothelium-dependent vasodila-
tion in the brachial artery. The effect of the
combination of simvastatin and L-arginine on
endothelium-dependent vasodilation was significantly
greater than that of either simvastatin alone or L-
arginine alone in the high serum level ADMA group.
Simvastatin alone had no significant effect on
endothelium-dependent vasodilation. Simvastatin, L-
arginine, as well as their combination led to a significant
increase in endothelium-dependent vasodilation in low
serum level ADMA group [32]. ADMA is a competitive
inhibitor of eNOS, thus these investigations are explicable
by the potential effect of simvastatin on arginine uptake.
Statin treatment increases the arginine-induced prolonga-
tion of the closure time of human platelets. The short time
effect of statin can happen through the increase of eNOS
activity, thus this effect can be contribute to the increase
of arginine uptake [33].
Some contradicting results can be explained by the
fact that pravastatin increases arginine uptake. By
high arginine concentration (at least five times higher
than the physiological concentration) pravastatin does
not have a measurable effect on eNOS activity [28].
By low serum arginine concentration (ca. 50 μM) [21]
or reduced arginine transport [34] pravastatin can
increase arginine uptake significantly, thus increasing
eNOS activity as well. It has been observed in pre-
eclamptic pregnancies that arginine serum concentra-
tion is low [35].
Currently, statin treatment of pregnant women is
contra-indicated. Theoretically, utilization of statins
may help to fight against preeclampsia during preg-
nancy. The effect of pravastatin has been investigated
in animal preeclampsia models by some recent studies.
Ahmed A et al. reported that 20 μg/kg /day pravastatin
treatment prevents preeclamptic features (induced
Fig. 5 Arginine uptake of placental microsomes
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hypertension, glomerular injury, increased sVEGF level,
intrauterine retardation) in an immunologically-mediated
preeclampsia mouse model that spontaneously develops
pathological changes associated with preeclampsia [36].
Pravastatin restored angiogenic balance and prevented the
appeariance of preeclamptic symptoms in CBA/J x DBA/2
mice. Insertion of adenoviral vector (AdV-) expressing
sVEGFR into pregnant rats resulted in classic signs of pre-
eclampsia. The low dose pravastatin treatment (5 μg/
day) induced the expression of VEGF-like angiogenic
factor placental growth factor and ameliorated the
symptoms [37].
In some cases (e.g. in cases of pregnancies with higher
risk) it is considerable to use (prava) statin treatment. A
safe method could provide help in screening pregnant
women with higher risk. A statin treatment may help re-
duce sVEGFR1 and FFA levels, which are usually in-
creased in preeclampsia, and may also help handle
disfunctions due to it.
Conclusion
Our experiments indicate that pravastatin can also in-
crease eNOS activity rapidly. This effect is independ-
ent from the phosphorylation of eNOS Ser1177,
caveolin, and Hsp90. According to our observation,
the activity of eNOS is observed to be increased by
the rise of the enzyme’s substrate supply. Our find-
ings suggest that pravastatin may improve arginine
uptake of the placenta along with arginine substitu-
tion by insufficient arginine levels, thus decreasing the
symptoms of preeclampsia. Our results of arginine
uptake account for previous observations on the effect
of statins. In our work, there was a difference in con-
trol (39.8 ± 0.4 weeks) and preeclamptic (33.5 ± 3.0
weeks) gestational age. We opinionate, that differ-
ences in gestational age could not have influenced the
results. Expression of cationic amino acid transporters
(CAT-1, 4F2hc and LAT-1) are not reduced in pre-
eclamptic placenta (average gestational age 32.4 weeks
of preeclamptic women and 37.6 weeks of healthy
control women) [23].
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